Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide
Online Bulletin Board Support Group Users: click "Forum" to view archives and post messages. - hide
Show/Hide

"Ask the Docs" Webinar

July 22, 2020

If you missed today's "Ask the Docs" webinar featuring Dr. Terry Smith and Dr. Suzanne Freitag, you can now view the entire program on YouTube! Many thanks to Dr. Smith and Dr. Freitag for volunteering their time today, and to all the participants who submitted questions!

Read More

  • "Ask the Docs" Webinar

    July 22, 2020

    If you missed today's "Ask the Docs" webinar featuring Dr. Terry Smith and Dr. Suzanne Freitag, you can now view the entire program on YouTube! Many thanks to Dr. Smith and Dr. Freitag for volunteering their time today, and to all the participants who submitted questions!

    Read More

  • COVID-19 Resources (Updated April 24)

    April 24, 2020

    Visit us on YouTube to view our new webinar: Graves' Disease, Thyroid Eye Disease and COVID-19 featuring Dr. Terry Smith and Dr. Don Kikkawa. (Approx. running time is 60 minutes).

    Stuck at home? Connect with your fellow patients online! We have several formats available for online support, including oneGRAVESvoice (a collaboration between the GDATF, Horizon Therapeutics, and rareLife solutions), the GDATF's online support forum, and our closed Facebook group (click Join/Visit in the ...

    Read More

  • Tepezza FDA Approval (teprotumumab-trbw)

    Jan. 21, 2020

    BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.

    Read More

  • Recent News

  • Recent Forum Posts

Questions? Problems? Please contact us at [email protected] or 877-643-3123.

GDATF on Facebook
Thank you to our Diamond Sponsors:
Quidel-Thyretain The Bell Charitable Foundation

Support the GDATF and become a member today!

© 2020 Graves' Disease & Thyroid Foundation